SURVIVAL FUNCTIONS IN 40-59 YEAR OLD MALE COHORTS ACCORDING TO THE PRESENCE OF ARTERIAL HYPERTENSION AND/OR MYOCARDIAL INFARCTION AND VARIOUS HIGH DENSITY LIPOPROTEIDES CONCENTRATIONS (BY THE 30-YEARS OBSERVATION)

Aim. To study interrelations of survival functions with the level of high-density lipoproteides cholesterol (CL HDL) in cohorts of 40-59 y. o. males with various cardiovascular disease status (CVD).

Material and methods. Randomly assigned 4 representative male groups aged 40-59 y. o. of Magnitogorsk district differed by the health status: almost healthy (n=174), hypertensive (n=149), with anamnesis of myocardial infarction (n=198), patients with infarction and arterial hypertension (n=154), – for prospective observation. The endpoint was death. To the cohorts mentioned the Cox model was applied for the 30-years survival functions, and the parameter revealed that explains the most significant influence on survival – HDL cholesterol, and the survival functions established for various levels of CL HDL. To compare survival rate in time points, endowment periods in different CL HDL groups, the relativity fields of survival functions were calculated using Kholmogorov-Smirnov criterion.

Results. The increase of CL HDL concentrations from 0,3 to 1,7 mmol/L in the cohorts mentioned is followed by significant increase of survival rate.

Conclusion. Characteristics of 30-years survival rate in the cohorts studied of 40-59 y.o. males with the increase of CL HDL demonstrates heterogeneity by the start, end and duration of the periods of significant differences of endowment graphs. The influence of baseline CL HDL concentrations on the 30-years survival functions among men not related to CVD. The influence of CL HDL on 30-year survival rate depends on CVD status and the disease periods.

1. Ingelsson E, Pencina MJ, Tofler GH, et al. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation 2007; 116(9): 984-92.

2. Sheng X, Murphy MJ, MacDonald TM, Wei L. Effect of statins on total cholesterol concentrations and cardiovascular outcomes in patients with diabetes mellitus: a population-based cohort study. Eur J Clin Pharmacol 2012; 68(8):1201-8.

3. Peter P. Toth, Kevin C. Maki. Practical lipid management: concepts and controversies. England. Publisher: Chichester, West Sussex, UK; Hoboken, NJ: Wiley-Blackwell, 2008. Description: xvii, 236 p. : ill. Russian (Тот П. П., Мэки К. К. Нарушения липидного обмена: пер. с англ./под ред. В. В. Кухарчука. М.: Изд-во ГЭОТАР-Медиа 2010; 272 с. с илл.).

4. Martsevich S, Ginsburg M, Kutishenko N, et al. Lyudertsy Stady of mortality in patients with acute myocardial infarction (LIS): the analysis of anamnestic predictors of in-hospital mortality. Cardivascular Therapy and Prevention 2013; 11(1):45-8. Russian (Марцевич С.Ю., Гинзбург М.Л., Кутишенко Н.П. и др. Люберецкое исследование смертности больных, перенесших острый инфаркт миокарда (ЛИС): анализ анамнестических факторов, определяющих смерть в стациона- ре. Кардиоваскулярная терапия и профилактика 2012; 11(1): 45-8).

5. Boytsov S, Kukharchuk V, Karpov Yu, et al. Subclinical atherosclerosis as a risk factor of cardiovascular events. Cardivascular Therapy and Prevention 2012; 11(3):82- 6. Russian (Бойцов С.А., Кухарчук В.В., Карпов Ю.А. и др. Субклинический атеросклероз как фактор риска сердечно-сосудистых осложнений. Кардиоваскулярная терапия и профилактика 2012; 11(3): 82-6).

6. Landi F, Russo A, Pahor M, et al. Serum high-density lipoprotein cholesterol levels and mortality in frail, community-living elderly. Gerontology 2008; 54(2): 71-8.

7. The Third universal definition of myocardial infarction: Recommendations of the European Society of Cardiologists Russ J Cardiol 2013; 2 (100), Appendix 1:1-16. Russian (Третье универсальное определение инфаркта миокарда: Рекомендации Европейского Общества Кардиологов. Российский кардиологи- ческий журнал 2013; 2(100), Приложение 1:1-16).

8. Belov VV, Menshchikov AA. Survival of cogorts of cardiac patients and healthy men aged 40-59 years: the 30-year follow-up data. Cardivascular Therapy and Prevention 2013; 12(2):74-9. Russian (Белов В. В., Меньщиков А. А. Выживаемость когорт пациентов кардиологического профиля и здоровых мужчин в возрасте 40-59 лет (данные 30-летнего наблюдения). Кардиоваскулярная терапия и профилактика 2013; 12(2):74-9).

9. Lang N, Secic V. How To Report Statistics in Medicine. Annotated Guidelines for Authors, Editors, and Reviewers. Moscow: Prakticheskaja medicina 2011; 480 p. Russian (Ланг Т.А., Сесик М. Как описывать статистику в медицине. Аннотированное руководство для авторов, редакторов и рецензентов. Пер. с англ. Москва: Практическая медицина 2011; 480 с).

10. Ermakov S, Gavrilova N S Primary statistical data processing on survival rate of organisms. Population gerontology. Under the editorship of E.V. Burlakova, A. A. Gavrilova. Sciences and a tehniki.-series: the General problems of biology. М.:VINITI 1987; V.6: 230-76. Russian (Ермаков С. П., Гаврилова Н. С. Первичная статистическая обработка данных по выживаемости организмов. Популяционная геронтология. Под ред. Е. В. Бурлакова, А. А. Гаврилова. Итоги науки и техники. Серия: Общие проблемы биологии. М.: ВИНИТИ 1987; Т.6: 230-76).

11. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285(19):2486-97.

12. Schwartz GG, Ollson AG, Ballantyne CM, et al.; dal-OUTCOMES Committees and Investigators. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 2009; 158(6):896-901. 13. Dislipidemias and an atherosclerosis. Biomarkers, diagnostics and treatment: a management For doctors. Under the editorship of the prof. R. Oganov. М: GEOTAR-MEDIA 2009; 160 pp. Russian (Дислипидемии и атеросклероз. Биомаркёры, диагностика и лечение: руководство для врачей. Под ред. проф., акад. РАМН Р.Г. Оганова. М. : ГЭОТАР–Медиа 2009; 160 с).

13. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, et al.; ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. EAS/ESC Guidelines for the management of dyslipidemias 2011. European Heart J 2011; 32: 1769-818.

14. Gratsiansky N. Statiny. Modern representations about hypolipidemic therapies. The review of recommendations EAS/ESC Guidelines for the management of dyslipidemias 2011. M 2011. Russian (Грацианский Н. А. Статины. Современные представления о гиполипидемической терапии. Обзор рекомендаций EAS/ESC Guidelines for the management of dyslipidemias 2011. М. 2011).

15. Wang WS, Wahlqvist ML, Hsu CC. Age – and gender – specific population attributable risks of metabolic disoders on all – cause and cardiovascular mortality in Taiwan. BMC Public Health 2012; 12: 111-23.

16. Cabrera MAS, de Andrado SM, Dip RM. Lipids and All – Cause Mortality among Older Adults: a 12 – year Follow – Up Study. Scientific World J 2012; 2012:930139. doi: 10.1100/2012/930139. Epub 2012 May 1.

17. Baigent C, Keech A, Kearney PM. Efficacy and Safety of cholesterol lowering treatment prospective meta – analysis of data from 90.056 participants in 14 randomised trials of statins. The Lancet 2005; 366(9493): 1267-78.

18. Nilsson G, Ohrvick J, Lonnberg I, Hedberg P. Ten – Year Survival in 75 – Year – Old Men and Women: Predictive Ability of Total Cholesterol, HDL – C, and LDL – C. Current Gerontology and Geriatrics Research 2009:158425. doi: 10.1155/2009/158425. Epub 2009 Apr 27.